Editor's note

Published March 2025. VacZine Analytics' commercial intelligence on the acne vaccines market is available in VAMV034 - Acne Vulgaris Vaccines Forecast, covering 10 developed markets to 2045 with interactive modelling.

Disease Burden and the Case for a Vaccine

Acne vulgaris is the most prevalent chronic skin condition globally. With an estimated 231.2 million prevalent cases in 2019 (Chen H et al, British Journal of Dermatology, 2022), the disease disproportionately affects adolescents - lifetime prevalence approaching 90% in this age group - but persists into adulthood in a substantial minority. Approximately 20-35% of cases are classified as moderate to severe. Isotretinoin, used in roughly 1-3% of cases, carries significant teratogenicity concerns that limit its use in women of childbearing age.

The therapeutic landscape has seen incremental improvement with retinoids, antibiotics, and biologics, but no mechanism has addressed the root microbiological cause: the dysregulation of Cutibacterium acnes within the pilosebaceous unit. A vaccine targeting this pathobiont would represent a fundamentally new approach.

Global disease burden · 2019
231.2m

Estimated prevalent cases of acne vulgaris globally. Source: Chen H et al, British Journal of Dermatology, 2022. Adolescent prevalence approaches 90%.

Sanofi SP0268: An mRNA Approach to an Old Problem

In 2021, Sanofi acquired Origimm Bio GmbH, a Vienna-based biotech developing a C. acnes vaccine. The lead candidate, SP0268, uses mRNA technology to elicit an immune response against surface antigens of C. acnes, targeting the inflammatory cascade responsible for moderate-to-severe lesions. The programme entered Phase 1/2 clinical development, making it the first industrially-backed acne vaccine to reach clinical evaluation.

The approach is notable for two reasons: it leverages Sanofi's growing mRNA manufacturing capabilities built partly in response to COVID-19, and the indication spans both inflammatory and non-inflammatory lesion types - suggesting potential as a monotherapy or adjunct in the moderate-to-severe population where current options are inadequate.

"A vaccine targeting Cutibacterium acnes would be the first mechanism to address the root microbiological cause of a condition affecting hundreds of millions globally."

The Commercial Opportunity

VacZine Analytics has modelled the commercial potential for acne vaccines across 10 developed markets in VAMV034 - Acne Vulgaris Vaccines Forecast. The analysis covers target product profiles for prophylactic and therapeutic indications, pricing scenarios to 2045, and payer access considerations across both private and publicly-funded healthcare systems. Given the size of the addressable population and the unmet need at the severe end of the spectrum, the market potential - if Phase 2 data are positive - is substantial.